Breaking News, Collaborations & Alliances

Galena, Dr. Reddy’s Enter Strategic NeuVax Pact

To expand development of breast cancer drug

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Galena Biopharma and Dr. Reddy’s Laboratories Ltd. have entered a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax is the immunodominant nonapeptide derived from the HER2 protein, a target for therapeutic intervention in breast cancer. Based on a successful Phase II trial, which achieved its primary endpoint of disease-free survival, the FDA granted NeuVax a Special Protocol Assessment (SPA) for a Phase III study.   “This partnership ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters